Table 1:
Patient demographics in the retrospective cohort and the VITdAL-ICU Cohort.
| Patient baseline characteristics | |||
|---|---|---|---|
| Retrospective Cohort | VITdAL ICU Cohort (N= 475) | ||
| N = 628 | Placebo N = 238 | Vitamin D3 N = 237 | |
| Gender: Female n (%) | 235 (37.4) | 83 (35) | 83 (35) |
| Age median (IQR) | 65 (52, 74.5) | 68 (56, 76) | 66 (55, 75) |
| SAPS II at ICU admission, mean (SD) | 29.4 (15.7) | 34.2 (15.7) | 32.4 (15) |
| TISS-28 mean (SD) | 31.7 (8.8) | 38.0 (8.2) | 37.7 (7.6) |
| 25-hydroxyvitamin D (ng/mL) mean (SD) | 19.6 (11.3) | 13.1 (4.3) | 13.0 (4.0) |
| ICU mortality n (%) | 83 (13.2) | 63 (26.5) | 54 (22.8) |
| Hospital mortality n (%) | 116 (18.5) | 84 (35.3) | 67 (28.3) |
| ICU length of stay (d) median (IQR) | 6 (3, 11) | 10.7 (0.1, 154.1) | 9.6 (0.2, 181) |
| Persistent Critical Illness n (%) | 181 (28.8) | 116 (48.7) | 106 (44.7) |
| Hospital length of stay (d) median (IQR) | 7 (0, 15) | 19.3 (0.1, 154.1) | 20.1 (0.2, 181) |
| ICU type | |||
| Cardiac Surgery n (%) | 102 (16.2) | 69 (29.0) | 68 (34.1) |
| Medical ICU n (%) | 228 (36.3) | 53 (22.3) | 52 (21.9) |
| Mixed Surgery-Medicine n (%) | 110 (17.5) | 58 (24.4) | 59 (24.9) |
| Neurologic ICU n (%) | 160 (25.5) | 61 (25.6) | 54 (22.8) |
| Neurosurgery ICU n (%) | 28 (4.5) | ||
SAPS II: Simplified acute physiology score; TISS-28: Therapeutic Intervention Score; ICU: Intensive care unit; IQR: interquartile range; d: day